Sökning: onr:"swepub:oai:lup.lub.lu.se:3b7a5845-040c-43da-8b93-d050ea3c29bc" >
Clinical efficacy o...
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
-
- Borch, Troels Holz (författare)
- Herlev Hospital
-
- Harbst, Katja (författare)
- Lund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,Melanoma Genomics,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Melanom,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Melanoma Study Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Melanoma,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Rana, Aynal Haque (författare)
- Herlev Hospital
-
visa fler...
-
- Andersen, Rikke (författare)
- Herlev Hospital
-
- Martinenaite, Evelina (författare)
- Herlev Hospital
-
- Kongsted, Per (författare)
- Herlev Hospital
-
- Pedersen, Magnus (författare)
- Herlev Hospital
-
- Nielsen, Morten (författare)
- Herlev Hospital
-
- Kjeldsen, Julie Westerlin (författare)
- Herlev Hospital
-
- Kverneland, Anders Handrup (författare)
- Herlev Hospital
-
- Lauss, Martin (författare)
- Lund University,Lunds universitet,Melanoma Genomics,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Melanom,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Melanoma,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Hölmich, Lisbet Rosenkrantz (författare)
- University of Copenhagen,Herlev Hospital
-
- Hendel, Helle (författare)
- Herlev Hospital
-
- Met, Özcan (författare)
- Herlev Hospital,University of Copenhagen
-
- Jönsson, Göran (författare)
- Lund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,Melanoma Genomics,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Melanom,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Melanoma Study Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Melanoma,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Donia, Marco (författare)
- Herlev Hospital,University of Copenhagen
-
- Marie Svane, Inge (författare)
- University of Copenhagen,Herlev Hospital
-
visa färre...
-
(creator_code:org_t)
- 2021-07-01
- 2021
- Engelska.
-
Ingår i: Journal for ImmunoTherapy of Cancer. - : BMJ. - 2051-1426. ; 9:7
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://jitc.bmj.com...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Despite impressive response rates following adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, improvement is needed to increase the efficacy and broaden the applicability of this treatment. We evaluated the use of vemurafenib, a small-molecule BRAF inhibitor with immunomodulatory properties, as priming before TIL harvest and adoptive T cell therapy in a phase I/II clinical trial. METHODS: 12 patients were treated with vemurafenib for 7 days before tumor excision and during the following weeks until TIL infusion. TILs were grown from tumor fragments, expanded in vitro and reinfused to the patient preceded by a lymphodepleting chemotherapy regimen and followed by interleukin-2 infusion. Extensive immune monitoring, tumor profiling and T cell receptor sequencing were performed. RESULTS: No unexpected toxicity was observed, and treatment was well tolerated. Of 12 patients, 1 achieved a complete response, 8 achieved partial response and 3 achieved stable disease. A PR and the CR are ongoing for 23 and 43 months, respectively. In vitro anti-tumor reactivity was found in TILs from 10 patients, including all patients achieving objective response. Serum and tumor biomarker analyses indicate that baseline cytokine levels and the number of T cell clones may predict response to TIL therapy. Further, TCR sequencing suggested skewing of TCR repertoire during in vitro expansion, promoting certain low frequency clonotypes. CONCLUSIONS: Priming with vemurafenib before infusion of TILs was safe and feasible, and induced objective clinical responses in this cohort of patients with checkpoint inhibitor-resistant metastatic melanoma. In this trial, vemurafenib treatment seemed to decrease attrition and could be considered to bridge the waiting time while TILs are prepared.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- adoptive
- clinical trials as topic
- immunotherapy
- lymphocytes
- melanoma
- tumor-infiltrating
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Borch, Troels Ho ...
-
Harbst, Katja
-
Rana, Aynal Haqu ...
-
Andersen, Rikke
-
Martinenaite, Ev ...
-
Kongsted, Per
-
visa fler...
-
Pedersen, Magnus
-
Nielsen, Morten
-
Kjeldsen, Julie ...
-
Kverneland, Ande ...
-
Lauss, Martin
-
Hölmich, Lisbet ...
-
Hendel, Helle
-
Met, Özcan
-
Jönsson, Göran
-
Donia, Marco
-
Marie Svane, Ing ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal for Immu ...
- Av lärosätet
-
Lunds universitet